Cynthia Dilauro
Internal Medicine · Cuyahoga Falls, OHNPI 1023100476
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 392 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AbbVie at 28.9% of the total. 2022 is the largest year on record at $1,658, 2.5 times the $658 reported in 2019. Among internal medicine clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 392 payments — averaging $12.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$574
- Pfizer$570
- AstraZeneca$347
- Lilly USA, LLC$226
- Amgen$203
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,89398%
- Education$992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 131 | $1,443 |
| Novo Nordisk | 61 | $574 |
| Pfizer | 46 | $570 |
| AstraZeneca | 12 | $347 |
| Lilly USA, LLC | 18 | $226 |
| Amgen | 13 | $203 |
| Boehringer Ingelheim | 13 | $190 |
| Novartis | 10 | $169 |
| Biohaven Pharmaceuticals, Inc. | 12 | $155 |
| GSK | 11 | $152 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $133 |
| Astellas Pharma US Inc | 3 | $109 |
| Endo Pharmaceuticals Inc. | 6 | $98 |
| Teva Pharmaceuticals USA, Inc. | 5 | $72 |
| Merck | 5 | $65 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $56 |
| Jazz Pharmaceuticals Inc. | 4 | $54 |
| Kowa Pharmaceuticals America, Inc. | 3 | $39 |
| Nevro Corp. | 2 | $38 |
| Eisai Inc. | 2 | $28 |
| Bayer | 1 | $25 |
| Biogen | 1 | $25 |
| Johnson & Johnson | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 2 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Bausch Health US, LLC | 1 | $15 |
| Abbott | 1 | $13 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
| Vivus LLC | 1 | $12 |
| Inogen, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$121
How this compares
$4,992 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 55 | $50,426 |
| EliquisApixaban | 42 | $46,179 |
| MounjaroTirzepatide | 42 | $40,807 |
| AristadaAripiprazole Lauroxil | 13 | $38,699 |
| MyrbetriqMirabegron | 18 | $22,171 |
| VraylarCariprazine Hcl | 11 | $18,501 |
| SynthroidLevothyroxine Sodium | 95 | $7,042 |
| BelsomraSuvorexant | 13 | $5,391 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $3,283 |
| Levothyroxine Sodium | 239 | $2,682 |
| Valsartan | 59 | $2,315 |
| Gabapentin | 123 | $2,281 |
| Estradiol | 29 | $2,142 |
| Donepezil Hcl | 34 | $2,003 |
| Celecoxib | 20 | $1,939 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $574 | $50,42655 claims |
| PfizerEliquis, Paxlovid | $570 | $47,60859 claims |
| Lilly USA, LLCMounjaro | $226 | $40,80742 claims |
| AbbVieVraylar, Synthroid | $1,443 | $25,543106 claims |
| Astellas Pharma US IncMyrbetriq | $109 | $22,17118 claims |
| MerckBelsomra | $65 | $5,39113 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $2,682239 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Cuyahoga Falls
- Hassan MalikAkron$1.7M
- Cyrus HarrisCleveland$726K
- Nina DeepWesterville$614K
- Necklall KhooblallAustintown$448K
- Daniel WeissMentor$406K
- Richard KimDayton$326K
- Marina MagreyCleveland$312K
- Lisa LarkinCincinnati$276K
- Gregg FaimanMayfield Hts$274K
- Vincent MartinCincinnati$261K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.